Top

Cancer Causes & Control

Published in:

01-09-2009 | Original Paper

Race in ovarian cancer treatment and survival: a systematic review with meta-analysis

Authors: Mishka Terplan, Erica J. Smith, Sarah M. Temkin

Published in: Cancer Causes & Control | Issue 7/2009

Abstract

Objective

There has long been recognition of racial disparities in cancer treatment and survival. In order to investigate the etiology of racial disparities in ovarian cancer, we undertook a systematic review of the published literature.

Methods

Focusing on North America, our search of MEDLINE, PsychInfo, and EMBASE databases recovered 513 abstracts of which 98 underwent full text screening resulting in 24 studies included in the final review. After assessing heterogeneity, results were pooled where possible in a meta-analysis using a random effects model.

Results

Eight articles reported treatment outcomes, nine survival, and seven both. Overall African Americans were less likely to receive any form of surgical treatment for ovarian cancer [pooled relative risk (RR) 1.17 (95% confidence interval (CI): 1.10, 1.23)] compared with white women. Although the majority of the included articles reporting survival outcomes did not control for known covariates such as medical co-morbidities or treatment, we were able to pool the unadjusted results from eight articles. Taken together the meta-analysis of 106,704 women did not find a difference in five-year survival between whites and African Americans, RR 1.07 (95% CI: 0.97, 1.18). When the results were stratified by year of cancer diagnosis, studies which captured patients prior to 1985 yielded a five-year RR of survival for whites compared to African Americans of 0.93 (95% CI: 0.89, 0.97) compared with 1.17 (95% CI: 1.05, 1.31) after 1985.

Conclusion

These results suggest that racial disparities in ovarian cancer are not due to underlying biological differences rather to the unequal application of existing treatments.

Jemal A, Siegel R, Ward E et al (2008) Cancer statistics, 2008. CA Cancer J Clin 58:71–96. doi:10.3322/CA.2007.0010 PubMedCrossRef

Kosary CL (1994) FIGO stage, histology, histologic grade, age and race as prognostic factors in determining survival for cancers of the female gynecological system: an analysis of 1973–87 SEER cases of cancers of the endometrium, cervix, ovary, vulva, and vagina. Semin Surg Oncol 10:31–46. doi:10.1002/ssu.2980100107 PubMedCrossRef

Aletti GD, Dowdy SC, Gostout BS et al (2006) Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstet Gynecol 107:77–85PubMed

Allen DG, Heintz AP, Touw FW (1995) A meta-analysis of residual disease and survival in stage III and IV carcinoma of the ovary. Eur J Gynaecol Oncol 16:349–356PubMed

Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20:1248–1259. doi:10.1200/JCO.20.5.1248 PubMedCrossRef

Chi DS, Liao JB, Leon LF et al (2001) Identification of prognostic factors in advanced epithelial ovarian carcinoma. Gynecol Oncol 82:532–537. doi:10.1006/gyno.2001.6328 PubMedCrossRef

Eisenkop SM, Friedman RL, Wang HJ (1998) Complete cytoreductive surgery is feasible and maximizes survival in patients. Gynecol Oncol 69:103–108. doi:10.1006/gyno.1998.4955 PubMedCrossRef

Hoskins WJ, McGuire WP, Brady MF et al (1994) The effect of diameter of largest residual disease on survival after primary. Am J Obstet Gynecol 170:974–979PubMed

Le T, Krepart GV, Lotocki RJ, Heywood MS (1997) Does debulking surgery improve survival in biologically aggressive ovarian. Gynecol Oncol 67:208–214. doi:10.1006/gyno.1997.4839 PubMedCrossRef

10.

Goff BA, Matthews BJ, Larson EH et al (2007) Predictors of comprehensive surgical treatment in patients with ovarian cancer. Cancer 109:2031–2042. doi:10.1002/cncr.22604 PubMedCrossRef

11.

Goff BA, Matthews BJ, Wynn M, Muntz HG, Lishner DM, Baldwin LM (2006) Ovarian cancer: patterns of surgical care across the United States. Gynecol Oncol 103:383–390. doi:10.1016/j.ygyno.2006.08.010 PubMedCrossRef

12.

Barnholtz-Sloan JS, Tainsky MA, Abrams J et al (2002) Ethnic differences in survival among women with ovarian carcinoma. Cancer 94:1886–1893. doi:10.1002/cncr.10415 PubMedCrossRef

13.

Ries LAG, Melbert D, Krapcho M, Stinchcomb DG, Howlader N, Horner MJ, Mariotto A, Miller BA, Feuer EJ, Altekruse SF, Lewis DR, Clegg L, Eisner MP, Reichman M, Edwards BK (eds). SEER Cancer Statistics Review, 1975–2005, National Cancer Institute. Bethesda, MD. http://seer.cancer.gov/csr/1975_2005

14.

McGuire V, Herrinton L, Whittemore AS (2002) Race, epithelial ovarian cancer survival, and membership in a large health maintenance organization. Epidemiology 13:231–234. doi:10.1097/00001648-200203000-00021 PubMedCrossRef

15.

Chan JK, Zhang M, Hu JM, Shin JY, Osann K, Kapp DS (2008) Racial disparities in surgical treatment and survival of epithelial ovarian cancer in United States. J Surg Oncol 97:103–107. doi:10.1002/jso.20932 PubMedCrossRef

16.

Parham GP, Hicks ML (2005) Racial disparities affecting the reproductive health of African-American women. Med Clin North Am 89:935–943 941PubMedCrossRef

17.

Barnholtz-Sloan JS, Schwartz AG, Qureshi F, Jacques S, Malone J, Munkarah AR (2003) Ovarian cancer: changes in patterns at diagnosis and relative survival over the last three decades. Am J Obstet Gynecol 189:1120–1127. doi:10.1067/S0002-9378(03)00579-9 PubMedCrossRef

18.

Harlan LC, Clegg LX, Trimble EL (2003) Trends in surgery and chemotherapy for women diagnosed with ovarian cancer in the United States. J Clin Oncol 21:3488–3494. doi:10.1200/JCO.2003.01.061 PubMedCrossRef

19.

Du X, Sun C, Milam M, Bodurka D, Fang S (2007) Ethnic differences in socioeconomic status, diagnosis, treatment, and survival among older women with epithelial ovarian cancer. Int J Gynecol Cancer 18(4):660–669PubMedCrossRef

20.

Parham G, Phillips JL, Hicks ML et al (1997) The national cancer data base report on malignant epithelial ovarian carcinoma in African–American women. Cancer 80:816–826. doi:10.1002/(SICI)1097-0142(19970815)80:4<816::AID-CNCR21>3.0.CO;2-V PubMedCrossRef

21.

Cress RD, O’Malley CD, Leiserowitz GS, Campleman SL (2003) Patterns of chemotherapy use for women with ovarian cancer: a population-based study. J Clin Oncol 21:1530–1535. doi:10.1200/JCO.2003.08.065 PubMedCrossRef

22.

Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539–1558. doi:10.1002/sim.1186 PubMedCrossRef

23.

Glasziou PP, Sanders SL (2002) Investigating causes of heterogeneity in systematic reviews. Stat Med 21:1503–1511. doi:10.1002/sim.1183 PubMedCrossRef

24.

Alberts DS, Dahlberg S, Green SJ et al (1993) Analysis of patient age as an independent prognostic factor for survival in a phase III study of cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in stages III (suboptimal) and IV ovarian cancer. Cancer 71:618–627PubMed

25.

Averette HE, Janicek MF, Menck HR (1995) The national cancer data base report on ovarian cancer. American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 76:1096–1103. doi:10.1002/1097-0142(19950915)76:6<1096::AID-CNCR28207606263.0.CO;2-4 PubMedCrossRef

26.

Chan JK, Urban R, Cheung MK et al (2006) Ovarian cancer in younger vs older women: a population-based analysis. Br J Cancer 95:1314–1320. doi:10.1038/sj.bjc.6603457 PubMedCrossRef

27.

Chan JK, Munro EG, Cheung MK et al (2007) Association of lymphadenectomy and survival in stage I ovarian cancer patients. Obstet Gynecol 109:12–19PubMed

28.

Chan JK, Urban R, Hu JM et al (2007) The potential therapeutic role of lymph node resection in epithelial ovarian cancer: a study of 13 918 patients. Br J Cancer 96:1817–1822. doi:10.1038/sj.bjc.6603803 PubMedCrossRef

29.

McGuire V, Jesser CA, Whittemore AS (2002) Survival among U.S. women with invasive epithelial ovarian cancer. Gynecol Oncol 84:399–403. doi:10.1006/gyno.2001.6536 PubMedCrossRef

30.

Morgan MA, Behbakht K, Benjamin I, Berlin M, King SA, Rubin SC (1996) Racial differences in survival from gynecologic cancer. Obstet Gynecol 88:914–918. doi:10.1016/S0029-7844(96)00342-0 PubMedCrossRef

31.

Munoz KA, Harlan LC, Trimble EL (1997) Patterns of care for women with ovarian cancer in the United States. J Clin Oncol 15:3408–3415PubMed

32.

O’Malley CD, Cress RD, Campleman SL, Leiserowitz GS (2003) Survival of Californian women with epithelial ovarian cancer, 1994–1996: a population-based study. Gynecol Oncol 91:608–615. doi:10.1016/j.ygyno.2003.08.010 PubMedCrossRef

33.

Polsky D, Armstrong KA, Randall TC et al (2006) Variation in chemotherapy utilization in ovarian cancer: the relative contribution of geography. Health Serv Res 41:2201–2218. doi:10.1111/j.1475-6773.2006.00596.x PubMedCrossRef

34.

Smith JP, Day TG Jr (1979) Review of ovarian cancer at the University of Texas Systems Cancer Center. M.D. Anderson Hospital and Tumor Institute. Am J Obstet Gynecol 135:984–993PubMed

35.

Sundararajan V, Hershman D, Grann VR, Jacobson JS, Neugut AI (2002) Variations in the use of chemotherapy for elderly patients with advanced ovarian cancer: a population-based study. J Clin Oncol 20:173–178. doi:10.1200/JCO.20.1.173 PubMedCrossRef

36.

Winter WEIII, Maxwell GL, Tian C et al (2007) Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 25:3621–3627. doi:10.1200/JCO.2006.10.2517 PubMedCrossRef

37.

Young J, Ries LG, Pollack ES (1984) Cancer patient survival among ethnic groups in the United States. J Natl Cancer Inst 73:341–352PubMed

38.

Ferreira E, Carceller AM, Agogue C et al (2007) Effects of selective serotonin reuptake inhibitors and venlafaxine during pregnancy in term and preterm neonates. Pediatrics 119:52–59. doi:10.1542/peds.2006-2133 PubMedCrossRef

39.

Omura G, Blessing JA, Ehrlich CE et al (1986) A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin. Cancer 57:1725–1730. doi:10.1002/1097-0142(19860501)57:9<1725::AID-CNCR2820570903>3.0.CO;2-J PubMedCrossRef

40.

Omura GA, Bundy BN, Berek JS, Curry S, Delgado G, Mortel R (1989) Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin. J Clin Oncol 7:457–465PubMed

41.

Griffiths CT (1975) Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr 42:101–104PubMed

42.

Farley JH, Tian C, Rose GS, Brown CL, Risinger JI, Maxwell GL (2008) Ethnicity and clinical outcomes for advanced epithelial ovarian cancer patients treated by standard cisplatin/paclitaxel chemotherapy: a combined analysis of gynecologic oncology group clinical trials. J clin Oncol 26: abstr 5537

43.

Adler N, Stewart J, Cohen S et al. (2008) Reaching for a Healthier Life: facts on Socioeconomic Status and Health in the US. John D. and Catherine T MacArthur Foundation

44.

Sugiyama VE, Shin JY, Kapp DS et al. (2008) The effect of socioeconomic status on the survival of ovarian cancer patients. J Clin Oncol 26: p. abstr 5557

45.

Krieger N, Quesenberry C Jr, Peng T et al (1999) Social class, race/ethnicity, and incidence of breast, cervix, colon, lung, and prostate cancer among Asian, Black, Hispanic, and White residents of the San Francisco Bay Area, 1988–92 (United States). Cancer Causes Control 10:525–537. doi:10.1023/A:1008950210967 PubMedCrossRef

Title: Race in ovarian cancer treatment and survival: a systematic review with meta-analysis
Authors: Mishka Terplan
Erica J. Smith
Sarah M. Temkin
Publication date: 01-09-2009
Publisher: Springer Netherlands
Published in: Cancer Causes & Control / Issue 7/2009
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI: https://doi.org/10.1007/s10552-009-9322-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objective

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 7/2009

Incidence trends of invasive cervical cancer in the United States by combined race and ethnicity

Associations between endogenous sex hormone levels and mammographic and bone densities in premenopausal women

Components of the metabolic syndrome and risk of prostate cancer: the HUNT 2 cohort, Norway

Serum total cholesterol and the risk of breast cancer in postmenopausal Korean women

Bisphenol A may reduce the efficacy of androgen deprivation therapy in prostate cancer

The association of atopic diseases with breast, prostate, and colorectal cancers: a meta-analysis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer